The 5-HTTLPR promoter polymorphism in SLC6A4 is among the most studied gene-behavior associations in psychiatry. The short (S) allele reduces serotonin transporter expression — associated with elevated amygdala reactivity, stress sensitivity, and mood vulnerability under adversity. Directly relevant to anxiety, depression, and SSRI response.
The Val158Met variant in COMT determines dopamine clearance rate in the prefrontal cortex. Val/Val ("warriors") clear dopamine rapidly — performing better under stress but with lower baseline working memory. Met/Met ("worriers") have slower clearance — superior executive function at baseline, but greater vulnerability to acute stress and performance degradation under pressure.
MAOA encodes monoamine oxidase A, which catabolizes serotonin, dopamine, and norepinephrine. Low-activity variants associate with elevated neurotransmitter levels and altered stress response — relevant to anxiety regulation, impulse control, and mood stability under chronic stress.
The Val66Met polymorphism in BDNF reduces activity-dependent BDNF secretion. This affects synaptic plasticity, memory consolidation, and the brain's response to exercise, stress, and antidepressant treatment. The Met allele associates with smaller hippocampal volume and greater stress vulnerability — but also with a more responsive cortisol system.
FKBP5 variants affect glucocorticoid receptor sensitivity and HPA axis reactivity — the primary stress response system. Certain genotypes associate with altered cortisol clearance and a higher risk of developing stress-related conditions following adverse events. Supplement and lifestyle interventions can be specifically targeted to this genetic risk.
Beyond physical health, MTHFR variants affect neurotransmitter synthesis by limiting methyl group availability for dopamine, serotonin, and norepinephrine production. Methylation-optimized supplement protocols (5-MTHF, methylcobalamin) can directly address the neurological implications of MTHFR low-function genotypes.
A structured profile of the user's serotonin, dopamine, and catecholamine system genetics — providing a biological framework for understanding mood patterns, stress responses, and cognitive tendencies that previously lacked a coherent explanation.
COMT, FKBP5, and cortisol pathway variants surfaced as a stress resilience profile — informing the type of stress management interventions most likely to be effective based on the user's specific neurogenetic architecture.
Methylation support (MTHFR-specific), magnesium (stress and NMDA receptor), omega-3s (neuroinflammation), and adaptogen responsiveness — genotype-specific supplement guidance for mental performance and mood stability.
Exercise type, sleep prioritization, and cognitive load management — each personalized to the neurogenetic profile. The lifestyle recommendations most likely to improve function for a given set of neurotransmitter genetics, not generic wellness advice.
Whether you're building a mental wellness app, a biohacking platform, or a clinical mental health tool — let's talk about what evidence-based genomic personalization looks like in your context.